Online inquiry

IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1460MR)

This product GTTS-WQ1460MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD22 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001185099.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 933
UniProt ID P20273
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ1460MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10619MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3303560
GTTS-WQ942MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-321
GTTS-WQ13996MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ10697MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA M-1095
GTTS-WQ4762MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BPS-804
GTTS-WQ2857MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG-570
GTTS-WQ11484MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MetMAb
GTTS-WQ2410MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 110
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW